Paper Details

  1. Home
  2. Paper Details

Role of Valganciclovir in Children with Congenital CMV Infection: A Review of the Literature.

Author: BuonsensoDanilo, ColussiLara, PataDavide, SalernoGilda, ScarlatoLucia, Turriziani-ColonnaArianna, Ulloa-GutierrezRolando, ValentiniPiero

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review evaluated the efficacy of Valganciclovir in preventing clinical sequelae in children with congenital cytomegalovirus (CMV) infection. The review found that neonatal antiviral treatments were only moderately effective in preventing clinical sequelae, and the therapy was well tolerated. The study concludes that randomized controlled trials are needed to establish the optimal dose and duration of Valganciclovir therapy for congenital CMV infection.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Cytomegalovirus (CMV) is the most common agent of congenital infection in humans. It is a main cause of neurodevelopmental delay and sensorineural hearing loss in infancy. Since the 2000s, a number of studies have used Valganciclovir as a therapy for children with congenital CMV infectio...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378502/

データ提供：米国国立医学図書館（NLM）

The role of Valganciclovir in treating congenital CMV infection

Congenital cytomegalovirus (CMV) infection is a significant health concern, particularly for infants, as it can lead to neurodevelopmental delays and sensorineural hearing loss. This review delves into the use of Valganciclovir as a therapy for children with congenital CMV infection. It's like exploring a new territory in the vast desert of medical research, seeking a cure for a challenging ailment.

Valganciclovir: A potential weapon against CMV infection

The researchers reviewed published literature, examining the efficacy and safety of Valganciclovir in treating congenital CMV infection. It's like analyzing the effectiveness of different weapons in battling a desert storm. They discovered that Valganciclovir is generally well-tolerated but that the therapeutic protocols used varied significantly, making it difficult to draw definitive conclusions about its efficacy.

The need for further research

This review highlights the need for larger, well-designed randomized controlled trials to determine the optimal dosage, duration, and effectiveness of Valganciclovir in treating congenital CMV infection. It's like conducting a comprehensive survey of the desert, identifying the best routes and resources for combating this challenging condition.

Dr. Camel's Conclusion

This review provides valuable insights into the potential of Valganciclovir in treating congenital CMV infection, but more research is needed to fully understand its effectiveness and optimize its use. It's a journey of discovery, and we must continue to explore the vast desert of medical research to find better treatments for this serious condition.
Date :
  1. Date Completed n.d.
  2. Date Revised 2023-07-31
Further Info :

Pubmed ID

37508743

DOI: Digital Object Identifier

PMC10378502

Related Literature

Article Analysis
・Side Effects of valganciclovir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.